HitGen (SHSE:688222) DeferredTaxAndRevenue: ¥0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688222 HitGen Inc SHSE:688222
90 GF Score
Price ¥33.91
GF Value ¥26.19
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is HitGen DeferredTaxAndRevenue?

HitGen SHSE:688222 +9.81% 90 DeferredTaxAndRevenue is ¥0.0 Mil as of Mar. 2026. GuruFocus rates SHSE:688222 with a GF Score™ of 90/100 and a GF Value™ of ¥26.19 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

HitGen's current deferred tax and revenue for the quarter that ended in Mar. 2026 was ¥0.0 Mil.

HitGen DeferredTaxAndRevenue Related Terms

HitGen DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for HitGen's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HitGen DeferredTaxAndRevenue Chart

HitGen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HitGen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:688222
90GF Score
HitGen Inc SHSE:688222
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of ¥0.0 Mil mean?
HitGen (SHSE:688222) has a DeferredTaxAndRevenue of ¥0.0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on HitGen.
Is HitGen's DeferredTaxAndRevenue too high?
HitGen's current DeferredTaxAndRevenue is ¥0.0 Mil. Overall, HitGen has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HitGen's DeferredTaxAndRevenue compare to VRTX and REGN?
HitGen's DeferredTaxAndRevenue of ¥0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on HitGen. HitGen's current DeferredTaxAndRevenue is ¥0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HitGen stock overvalued right now?
Based on GuruFocus' analysis, HitGen (SHSE:688222) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥26.19, compared to a current price of ¥33.91 — trading 29.5% above its estimated fair value. The current DeferredTaxAndRevenue is ¥0.0 Mil. HitGen's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For HitGen (SHSE:688222), the current DeferredTaxAndRevenue is ¥0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HitGen (SHSE:688222) Overvalued in 2026?

Based on GuruFocus' analysis, HitGen stock appears to be overvalued. The current stock price of ¥33.91 is trading 29.5% above its estimated GF Value™ of ¥26.19. GuruFocus considers HitGen to be Modestly Overvalued.

Key valuation signals for SHSE:688222:

  • DeferredTaxAndRevenue: ¥0.0 Mil
  • GF Value™: ¥26.19 vs. price of ¥33.91 (29.5% above fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the SHSE:688222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HitGen Business Description

Address Section 2, Biocity Middle Road, Chengdu Tianfu International Biological City, No. 18, Shuangliu District, Sichuan Province, Chengdu, CHN, 610093
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
90GF Score

Get the complete analysis for SHSE:688222

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥33.91
Price
¥26.19
GF Value